Rhabdomyoblastic differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy

被引：0
|
作者：
Liegl, B.
Hornick, J. L.
Antonescu, C. R.
Corless, C. L.
Letcher, C. D. M.
机构：
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
来源：
LABORATORY INVESTIGATION | 2008年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
50
引用
收藏
页码：14A / 14A
页数：1
相关论文
共 50 条
  • [1] Rhabdomyoblastic differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy
    Liegl, B.
    Hornick, J. L.
    Antonescu, C. R.
    Corless, C. L.
    Fletcher, C. D. M.
    MODERN PATHOLOGY, 2008, 21 : 14A - 14A
  • [2] Rhabdomyosarcomatous Differentiation in Gastrointestinal Stromal Tumors After Tyrosine Kinase Inhibitor Therapy A Novel Form of Tumor Progression
    Liegl, Bernadette
    Hornick, Jason L.
    Antonescu, Cristina R.
    Corless, Christopher L.
    Fletcher, Christopher D. M.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (02) : 218 - 226
  • [3] Duodenal Gastrointestinal Stromal Tumors and Neoadjuvant Tyrosine Kinase Inhibitor Therapy
    Kelly, Colleen H.
    Sipok, Arkadii
    Ramsey, Lolita
    Gnerlich, Jennifer
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (SUPPL 1) : S168 - S168
  • [4] Optimizing Tyrosine Kinase Inhibitor Therapy in Gastrointestinal Stromal Tumors: Exploring the Benefits of Continuous Kinase Suppression
    Le Cesne, Axel
    Blay, Jean-Yves
    Reichardt, Peter
    Joensuu, Heikki
    ONCOLOGIST, 2013, 18 (11): : 1192 - 1199
  • [5] Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors
    Brian K. Bednarski
    Dejka M. Araujo
    Min Yi
    Keila E. Torres
    Alexander Lazar
    Jonathan C. Trent
    Janice N. Cormier
    Peter W. T. Pisters
    Dina Chelouche Lev
    Raphael E. Pollock
    Barry W. Feig
    Kelly K. Hunt
    Annals of Surgical Oncology, 2014, 21 : 2499 - 2505
  • [6] Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors
    Bednarski, Brian K.
    Araujo, Dejka M.
    Yi, Min
    Torres, Keila E.
    Lazar, Alexander
    Trent, Jonathan C.
    Cormier, Janice N.
    Pisters, Peter W. T.
    Lev, Dina Chelouche
    Pollock, Raphael E.
    Feig, Barry W.
    Hunt, Kelly K.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (08) : 2499 - 2505
  • [7] Gastrointestinal stromal tumors respond to tyrosine kinase-targeted therapy
    Maki R.G.
    Current Treatment Options in Gastroenterology, 2004, 7 (1) : 13 - 17
  • [8] Analysis at tumor-infiltrating immune cells gastrointestinal stromal tumors (GIST) after tyrosine kinase inhibitor therapy.
    Hohenberger, Peter
    Zhao, Wenyi
    Deligiarmi, Maria
    Simon-Keller, Katia
    Cao, Hui
    Marx, Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Disparities in tyrosine kinase inhibitor use in older patients with gastrointestinal stromal tumors
    Ho, Thanh P.
    Dykhoff, Hayley
    Sangaralingham, Lindsey R.
    Siontis, Brittany L.
    Grotz, Travis E.
    Okuno, Scott H.
    Robinson, Steven I.
    JOURNAL OF GERIATRIC ONCOLOGY, 2023, 14 (04)
  • [10] Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era
    Turley, Ryan S.
    Peng, Peter D.
    Reddy, Srinevas K.
    Barbas, Andrew S.
    Geller, David A.
    Marsh, J. Wallis
    Tsung, Allan
    Pawlik, Timothy M.
    Clary, Bryan M.
    CANCER, 2012, 118 (14) : 3571 - 3578
12345